



Please complete ALL information below and fax your request to 1-888-671-5285

### Nucala® Prior Authorization Request Form (Page 1 of 2)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information <small>(required)</small>			Provider Information <small>(required)</small>		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:
Medication Information <small>(required)</small>					
Medication Name:			Strength:		Dosage Form:
<input type="checkbox"/> Check if <b>generic substitution</b> is acceptable			Directions for Use:		
<input type="checkbox"/> Check if request is for <b>continuation of therapy</b>					
Clinical Information <small>(required)</small>					
<b>Select the diagnosis below:</b> <input type="checkbox"/> Eosinophilic granulomatosis with polyangitis (EGPA) <input type="checkbox"/> Severe eosinophilic asthma <input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____					
<b>Prescriber's Specialty:</b> Select if Nucala is prescribed by or in consultation with one of the following specialists: <input type="checkbox"/> Allergist/Immunologist <input type="checkbox"/> Pulmonologist <input type="checkbox"/> Rheumatologist					
<b>For eosinophilic granulomatosis with polyangitis (EGPA), answer the following:</b> Has the patient's disease relapsed or is the disease refractory to standard of care therapy (i.e., corticosteroid treatment with or without immunosuppressive therapy)? <input type="checkbox"/> Yes <input type="checkbox"/> No Is the patient currently receiving corticosteroid therapy (e.g., prednisolone, prednisone)? <input type="checkbox"/> Yes <input type="checkbox"/> No <b>Reauthorization:</b> Is there documentation that the patient has had a positive clinical response to therapy (e.g., increase in remission time)? <input type="checkbox"/> Yes <input type="checkbox"/> No					
<b>For severe eosinophilic asthma, answer the following:</b> Select to confirm the asthma is an eosinophilic phenotype as defined by the following: <input type="checkbox"/> Baseline (pre-treatment) peripheral blood eosinophil level greater than or equal to 150 cells/microliter <input type="checkbox"/> Peripheral blood eosinophil levels were greater than or equal to 300 cells/microliter within the past 12 months Has the patient had at least one or more asthma exacerbations requiring systemic corticosteroids within the past 12 months? <input type="checkbox"/> Yes <input type="checkbox"/> No Has the patient had any prior intubation for an asthma exacerbation? <input type="checkbox"/> Yes <input type="checkbox"/> No Has the patient had prior asthma-related hospitalization within the past 12 months? <input type="checkbox"/> Yes <input type="checkbox"/> No Select if the patient is currently being treated with, or has a contraindication, or intolerance to the following: <input type="checkbox"/> High-dose inhaled corticosteroid (ICS) (e.g., greater than 500 mcg fluticasone propionate equivalent/day) <input type="checkbox"/> Additional asthma controller medication (e.g., leukotriene receptor antagonist, long-acting beta-2 agonist [LABA], theophylline) <input type="checkbox"/> One maximally-dosed combination ICS/LABA product (e.g., Advair [fluticasone propionate/salmeterol], Dulera [mometasone/formoterol], Symbicort [budesonide/formoterol])					
<b>&lt; continued on the next page &gt;</b>					

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of FutureScripts. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. **If you are not the intended recipient, please notify the sender immediately.**  
 Office use only: Nucala\_FSP\_2019Apr-W



Nucala® Prior Authorization Request Form (Page 2 of 2)
DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

< continued from the previous page >

Reauthorization:

Is there documentation the patient has had a positive clinical response to therapy (e.g., reduction in exacerbations, improvement in forced expiratory volume in 1 second [FEV1], decreased use of rescue medications)? [ ] Yes [ ] No

Select if the patient is currently being treated with, or has a contraindication, or intolerance to the following:

- [ ] Inhaled corticosteroid (ICS)
[ ] Additional asthma controller medication (e.g., leukotriene receptor antagonist, long-acting beta-2 agonist [LABA], theophylline)
[ ] A combination ICS/LABA product (e.g., Advair [fluticasone propionate/salmeterol], Dulera [mometasone/formoterol], Symbicort [budesonide/formoterol])

Quantity Limit Requests:

What is the quantity requested per MONTH? \_\_\_\_\_

What is the reason for exceeding the plan limitations?

- [ ] Titration or loading dose purposes
[ ] Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime)
[ ] Requested strength/dose is not commercially available
[ ] Other: \_\_\_\_\_

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.